The First Commission of the Colombian Senate officially started the discussion in the third debate of the constitutional reform that seeks to legalize the recreational use of cannabis in Colombia.
It is worth remembering that the initiative, whose rapporteur and co-author is the senator for the Historical Pact, María José Pizarro, seeks to modify “article 49 of the Political Constitution of Colombia, regularizes cannabis for adult use and other provisions are issued.”
If you want to read more about the legalization of recreational cannabis in Colombia and to find the most important cannabis news from around the world, download for free the Hemp.im mobile app.
The first commission approved the report of the legislative act to legalize cannabis for adult use in the country
During the presentation of the report, the congresswoman explained the four points by which it is proposed to legalize cannabis for recreational use in Colombia. Among them, there is the fight against drugs, the “legal framework that has been historic in the country”, in addition to the advances in the medical and scientific world on the use of this psychotropic substance and the economic gains and job creation that would be achieved with legalization.
“In terms of public health, it has been proven that cannabis has much less harmful effects. Not enough research has been done on the benefits it has in medicinal terms, as well as in other types of uses such as hemp to manufacture fabrics, including cosmetics that are already found in most supermarkets in our country. Then, in terms of health, it is much more harmful than alcohol or tobacco”, indicated the senator for the Historical Pact.
Under these arguments, the first commission approved the report of the legislative act to legalize cannabis for adult use in the country. However, in order to guarantee a better discussion of the initiative, a public hearing was called for this Monday, November 21st, so that the vote on the articles will be held on Tuesday, November 22.
The request for the public hearing was made by Senator Carlos Fernando Motoa of the Cambio Radical Party, who expressed that before voting on the articles, it is necessary for the congressmen to know all “the concepts that are in the file in order to make a correct decision”.
His colleague, Jorge Benedetti, added that the importance of the public hearing was based on “the argument of giving a greater discussion to this initiative and summoning the civil society to listen to their impressions on the matter”.
During the report of the legislative act to legalize cannabis for adult use, the senators for the Democratic Center Party, Paloma Valencia, and María Fernanda Cabal, presented two propositions of file, under arguments such as that marijuana causes a deterioration in the cognitive system.
Senator Cabal affirmed that she defends the liberties of each person, “but not over children”. For her part, Congresswoman Valencia said that “it is not true that by legalizing, illegal markets will end. What will end up happening is that the illegal market will take advantage of the legal channels. The great drug trafficking problem in Colombia is cocaine.”
The First Commission denied the proposals to file and postpone, although it was established that the public hearing will be mixed, in order to be able to vote on the articles.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in infobae, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
AbolerIS Pharma Closes a Round of €27 Million Led by Caixa Capital
AbolerIS Pharma is a biopharmaceutical company focused on revolutionizing immunotherapy for autoimmune and inflammatory diseases. Through an innovative antibody therapy...
The European Car Market Could Become Completely Sustainable by 2025, with the Adoption of Smaller EVs
According to an estimate by Transport & Environment, the six big European car manufacturers have abandoned the production of cheaper...
Mamacrowd Launches Five Campaigns with November 10th Deadline
To date, no Italian platform has obtained European authorization, so platforms cannot operate after November 10th. In the uncertainty, Mamacrowd...
Why Are Mexican Fintech Companies Increasingly Investing in Small Banks
Banks are not the only regulated institutions that fintech companies are investing in. Others are doing so with popular financial...
Vertex Obtains EMA Validation to Expand Indications for Kaftrio
Vertex is a global biotech company that invests in scientific innovation to create medicines for people with serious diseases. The...
Business7 days ago
Five Travel Stocks Investors Can’t Seem To Get Enough Of This Year
Fintech2 weeks ago
Banca Progetto Funding in Q1 Reaches €5 Billion and Disbursement to SMEs €1.5 Billion
Markets3 days ago
An Interesting Volatile Week for the Stock Markets
Fintech1 week ago
DeluPay Payment Method Comes with Fewer Commissions Paid by (e)-merchants